Journal Article

Quantification of Lorazepam and Lormetazepam in Human Breast Milk Using GC-MS in the Negative Chemical Ionization Mode

Patrick Lemmer, Serge Schneider, Annette Mühe and Robert Wennig

in Journal of Analytical Toxicology

Volume 31, issue 4, pages 224-226
Published in print May 2007 | ISSN: 0146-4760
Published online May 2007 | e-ISSN: 1945-2403 | DOI: http://dx.doi.org/10.1093/jat/31.4.224
Quantification of Lorazepam and Lormetazepam in Human Breast Milk Using GC-MS in the Negative Chemical Ionization Mode

More Like This

Show all results sharing these subjects:

  • Medical Toxicology
  • Toxicology (Non-medical)

GO

Show Summary Details

Preview

Lormetazepam (Loramet® is a benzodiazepine mainly used as an hypnotic to treat insomnia. Lorazepam (Temesta®) is used as an anxiolytic, tranquilizer, sedative, and anticonvulsant, and it is the major metabolite of Iormetazepam. In this study, we designed a method to simultaneously detect and quantify these substances in human breast milk. Solid-phase extraction of 2 mL of milk was followed by derivatization with a trimethylsilyl reagent. Separation and detection was performed using gas chromatography coupled to mass spectrometry in the negative chemical ionization mode. Calibration curves were linear in the ranges of 10–200 and 1–20 ng/mL for lorazepam and lormetazepam, respectively. Limits of detection were estimated at 0.016 ng/mL for lormetazepam and 0.100 ng/mL for lorazepam. Our method was applied to real case samples from a woman receiving both benzodiazepines. Lorazepam concentrations varied from 55.3 to 123.1 ng/mL, and lormetazepam concentrations varied from 1.7 to 7.3 ng/mL.

Journal Article.  0 words. 

Subjects: Medical Toxicology ; Toxicology (Non-medical)

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.